ILYA PHARMA AB
Desconocido
B-ACTIVE: Training of young scientists in the Biological regulation of the chemokine network to improve treatm...
ILYA PHARMA AB
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2022-DN-01
A number of pharmaceuticals targeting cytokine/chemokine storms in lungs are in development due to an urgent new unmet medical need strength...
2023-07-05 - 2027-12-31 | Financiado
2023-07-05 - 2027-12-31 | Financiado
WHILYAS-2: Wound healing ILYA style 2
ILYA PHARMA AB
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
ILYA PHARMA AB is a Swedish spin-out biotech company from Uppsala that develops next-generation biologics to treat wounds in skin and mucosa...
2020-11-26 - 2023-12-31 | Financiado
2020-11-26 - 2023-12-31 | Financiado
WHILYAS: Wound healing ILYA style
ILYA PHARMA AB
tramitó un
H2020:
H2020-SMEInst-2016-2017
The objective of the project is to develop the EV100 drug candidate to heal chronic wounds in patients with diabetes in a better, faster, an...
2018-04-03 - 2019-08-31 | Financiado
2018-04-03 - 2019-08-31 | Financiado
* No se disponen de datos de la empresa actual.